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Federal Regulation of Artificial
Insemination Donor Screening Practices:
An Opportunity for Law to Co-Evolve
with Medicine
I. Introduction
Artificial insemination is a popular treatment used to circumvent male infertility.' During 1986-1987, over 172,000 women in the
United States were artificially inseminated and as a result gave birth
to approximately 65,000 babies.2 Of these births, 35,000 resulted
from artificial insemination with the husband's semen or with an intimate partner's semen (AIH); the remaining 30,000 children were
conceived by artificial insemination with an anonymous donor's semen (AID).'
The demand for AID has tracked a significant increase in infertility among American couples during the past decade." Increased
infertility results from several demographic and physiological factors. Many couples are postponing childbearing into their later reproductive years and, as a consequence, some experience physical or
hormonal impediments to conception." Sexually transmitted diseases
that damage the reproductive tract may also play a large role, especially if the infection has gone undetected for a number of years.6
Concomitantly, the number of babies available for adoption has decreased during the past twenty years.7 Male infertility accounts for
an inability to conceive in about 30% of infertile couples. 8 Because
treatment for male infertility is often ineffective, the only reproductive option is artificial insemination by donor.'
1. Christopher L.R. Barratt et al., Donor Insemination-A Look to the Future, 54
TILITY & STERILITY

FER-

375 (1990) [hereinafter Barratt].

2. U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT, ARTIFICIAL INSEMINATION
PRACTICE IN THE U.S.: BACKGROUND PAPER, PUB. No. OTA-BP-BA-48 3 (1988) [hereinafter
OTA REPORT].
3. Id.at 3, 8.
4. William P. Hummel & Luther M. Talbert, Current Management of a Donor Insemination Program, 51 FERTILITY & STERILITY 919, 919 (1989) [hereinafter Hummel].
5. Id.
6. Id.
7. Ruth M. Greenblatt, et al., Screening Therapeutic InseminationDonorsfor Sexually
Transmitted Diseases: Overview & Recommendations, 46 FERTILITY & STERILITY 351, 351
(1986) [hereinafter Greenblatt].
8. Hummel, supra note 4, at 919.
9. Hummel, supra note 4, at 919.
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Physician-practitioners who use AID play an unusual medical
role comprising numerous duties and responsibilities. First, they have
a duty to safeguard the health of the recipient woman. 10 Second,
they have a duty to protect the health of the child to be conceived. 1
In this sense their role is similar to that of an obstetrician. Beyond
these roles, AID practitioners have duties to safeguard the donor's

health and protect his anonymity.' 2 Furthermore, as enablers of conception, AID practitioners have the power to shape the genetic com-

position of future generations. Therefore, they also owe a duty to
society."
The public's attention focused on the practice of artificial insemination in early 1990, when a New York City woman claimed
that her doctor had artificially inseminated her with the wrong semen."' Just after their marriage in 1985, the woman and her husband learned that he had cancer and that the required chemotherapy
would render him infertile.' 5 In order for the couple to conceive children after the chemotherapy, the husband contributed samples of his
semen to a sperm bank which froze the semen until the woman decided to become pregnant.' 6 The husband's health deteriorated, and
the woman decided to become pregnant and have a child as soon as
possible. 17 She was artificially inseminated and gave birth to a

daughter in 1986.18 Her husband died in 1989.1
The woman, who is White, alleged she knew immediately that
the child was not her husband's child because the child had features
that the woman described as Black. 20 DNA tests performed on re10. Colin D. Matthews et al., Screening of Karyotype and Semen Quality in an Artificial Insemination Program: Acceptance and Rejection Criteria, 40 FERTILITY & STERILITY
648, 648 (1983) [hereinafter Matthews].
11. Id.
12. Id.
13. See Lori B. Andrews, Ethical and Legal Aspects of In-Vitro Fertilization and Artificial Insemination by Donor, 14 UROL. CLINICS N. AM. 633, 638 (1987) [hereinafter
Andrews].
14. See, e.g., Barbara Kantrowitz & David A. Kaplan, Not the Right Father, NEWSWEEK, Mar. 19, 1990, at 50 [hereinafter Kantrowitz]. See also Robin Schatz, New Questions
in Sperm Mixup Case, NEWSDAY, April 22, 1990, at 7 [hereinafter New Questions]; Robin
Schatz, "Sperm Mixup" Spurs Debate, NEWSDAY, March 11, 1990, at 3 [hereinafter Debate];
Robin Schatz & Gale Scott, Sperm Mix-up Raises Doubts, NEWSDAY, March 10, 1990, at 4
[hereinafter Doubts].
15. See Kantrowitz, supra note 14, at 50.
16. See Kantrowitz, supra note 14, at 50.
17. See Kantrowitz, supra note 14, at 50.
18. See Kantrowitz, supra note 14, at 50.
19. See Kantrowitz, supra note 14, at 50.
20. See Kantrowitz, supra note 14, at 50. But see Doubts, supra note 14, at 4. The
Newsday article states that "after some time" the woman and her pediatrician noticed that the
child was Black.
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maining samples of the husband's sperm, as well as on the child,
showed that the husband's sperm could not have been used to con-

ceive the child.21
The woman sued her physician, his fertility clinic and the sperm
bank.22 The case is one of first impression for the nation and involves
charges of alleged faulty record-keeping by the sperm bank, malpractice and breach of contract on the part of the physician and his

clinic.23
Aside from this case, artificial insemination practices are the
subject of relatively little inquiry in both the popular and legal media. In contrast, a large body of medical literature demonstrates that
practitioners have been concerned about these practices for at least

twenty years. In particular, health care professionals are deeply concerned about the potential for AID to act as a vector for the spread
of numerous infectious diseases, most notably, Acquired Immu-

nodeficiency Syndrome (A.I.D.S.).2 ' Furthermore, practitioners are
concerned about the possible transmission of donors' genetic defects
to offspring.25 In response to these concerns, the profession has devel-

oped voluntary guidelines for AID practices.26 Some practitioners, as
well as government officials, are calling for governmental intervention in the form of recommendations or regulations.27 To date, the
21. See Doubts, supra note 14, at 3.
22. See Doubts, supra note 14, at 3. The case was filed in October, 1989 in New York
City and is still being litigated. The court has sealed the records, but names of the litigants
have been revealed by several sources. See New Questions, supra note 14, at 7.
23. See Kantrowitz, supra note 14, at 50.
24. See generally Edward P. Peterson et al., A.I.D. and AIDS- Too Close for Comfort,
49 FERTILITY & STERILITY 209 (1988).
25. See Matthews, supra note 10, at 653.
26. See, e.g., American Fertility Society, New Guidelines for the Use of Semen Donor
Insemination 1990, 53 FERTILITY & STERILITY, Supplement IS (1990) [hereinafter 1990
Guidelines].
27. Senator Albert Gore (D-TN) called for mandatory testing of anonymous sperm donors for A.I.D.S. Gore also expressed his intent to introduce legislation establishing a national
data bank for semen donors, which would enable children conceived by AID to access the
medical and genetic histories of their donor-biological fathers, but would also protect the identity of semen donors. Gregory Byrne, Artificial Insemination Report Prompts Call for Regulation, 241 SCIENCE 895 (1988); Charles Marwick, Artificial Insemination Faces Regulation,
Testing of Donor Semen, Other Measures, 260 J.A.M.A. 1339 (1988); Laurie Garrett, Study
Faults Sperm Bank Screening, NEWSDAY, August 10, 1988, at 7.
Fertility practitioners and some of the large commercial sperm banks also have expressed
the need for legislation regulating certain AID practices. See, e.g., Jerome K. Sherman, Synopsis of the Use of Frozen Human Semen Since 1964: State of the Art of Human Semen
Banking, 24 FERTILITY & STERILITY 397, 410 (1973) [hereinafter Sherman]; Stone, Compli-

cations and Pitfalls of Artificial Insemination, 23

CLIN. OBSTET.

&

GYNECOL.

667, 676

(1980) [hereinafter Stone]. But see Martin Curie-Cohen et al., Current Practice of Artificial
Insemination by Donor in the United States, 300 NEW ENG. J. MED. 585, 588 (1978) [hereinafter Curie-Cohen] (82.6% of physicians responding to the authors' survey of then current
AID practices opposed legislation that required keeping records for children or donors). This
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overall response of states and the federal government has been variable or non-existent.

This comment presents a rationale for federal regulation of artificial insemination donor screening practices. Part II is an overview
of AID procedures. Part III explores the need for scrutiny of AID
donor screening practices and suggests ways to improve and stand-

ardize the process of donor screening. Part IV examines efforts of
the profession, states and the federal government to provide recommendations and regulations. Part V analyzes the power of the federal government to regulate semen donor screening practices, and
Part VI presents specific recommendations for federal regulation of
semen donor screening for sexually transmitted diseases.
II.

Overview of AID Procedure
Ninety-five percent of artificial inseminations by donors are

sought because of husbands' infertility.2" The next most common
reason for AID is that the husband carries a deleterious gene and
fears transmitting it to his offspring.29 Genetic concerns include Rhfactor incompatibility, s" cystic fibrosis, 31 hemophilia,32 Huntingdon's
pre-A.I.D.S. concern appears to have reversed itself. A comprehensive federal report on infertility noted: "Federal regulation to assure safety of semen sold by sperm banks was viewed as
unreasonable by only a minority of sperm banks and individual physicians surveyed in 1987."
U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT, INFERTILITY MEDICAL
CHOICES, PUB. No. OTA-BA-358, 182-83 (1988) [hereinafter CHOICES].

& SOCIAL

In the legal community, most of the attention paid to AID has been directed at assessing
and analyzing the rights of the recipient couple, such as whether the infertile husband is the
legal father; the legal status of the child; the donor's right to privacy; and the donor's duty to
the child. A few commentators have noted the need for regulation of certain AID practices,
especially screening donors for infectious diseases. See, e.g., Andrews, supra note 13, at 63638, 639-41; Leonard G. Kamlet, Comment, Artificial Insemination A Model Statute, 24
CLEV. ST. L. REV. 341, 349, 351-54 (1975); Judith Lynn Bick Rice, The Need for Statutes
Regulating Artificial Insemination by Donors, 46 OHIO ST. L.J. 1055, 1071, 1074-76 (1985)
[hereinafter Rice]; Walter J. Wadlington, Baby M: Catalyst for Family Law Reform?, 5 J.
CONTEMP. HEALTH L. & POL'Y 1, 8-9 & note 35 (1989); Walter J. Wadlington, Artificial
Conception: The Challenge for Family Law, 69 VA. L. REV. 465, 485, 503 (1983).
28.

See Curie-Cohen, supra note 27, at 585. The authors conducted a survey of the AID

practices of 471 physicians. Curie-Cohen, supra note 27, at 585. There are many forms and
causes of male infertility. The most severe form is azoospermia, in which the male produces no
living sperm. The next most severe form is oligospermia, in which the concentration of living
sperm is extremely low. Spermatozoa also may have poor motility and abnormal morphology,
therefore rendering them ineffectual in conception. The causes of these forms of infertility
include genetic disorders, endocrine dysfunction and medication such as chemotherapy. Some
males may produce normal sperm but may be unable to ejaculate as a result of trauma, surgery or neurological disease. Hummel, supra note 4, at 919.
29. See Curie-Cohen, supra note 27, at 585.
30. See Curie-Cohen, supra note 27, at 585. Rh-factor refers to various genetically determined blood group types. EDWARD NovITSKI, HUMAN GENETICS 230-34 (2d ed. 1982)
[hereinafter NOVITSKI].
31. Cystic fibrosis is an inherited disease of certain duct glands, such as the pancreas,
that also affects the gastrointestinal and respiratory systems. The defective gene is recessive;
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disease 33 and Tay-Sachs disease. 4 The third most common request
for AID comes from women who wish to conceive children in the
absence of a husband or other intimate male partner. 35 Additional
reasons for requesting AID include the husband's paraplegia or his
3
exposure to mutagenic agents.

After a man is determined to be infertile, or if a suitable partner is unavailable, a physician evaluates the woman's ability to con-

ceive.3 7 Assuming she is able to conceive, the infertility practitioner
may then test her for the presence of sexually transmitted diseases
(STD's) and unusual genetic variants or defects. 8 Some clinics also
test the sperm donor for the presence of STD's.39
Artificial insemination practitioners obtain semen samples from
therefore, two copies of the gene are required for the disease to manifest itself. THE MERCK
MANUAL 2055 (15th ed. 1987). Cystic fibrosis is the most prevalent genetic disease in the
United States, affecting about 1 in 1600 Whites. It occurs much less frequently in Asians and
Blacks. The frequency of occurrence in normal carriers of the gene (people with one normal
and one defective copy of the gene) is much higher: 1 in 20 people. NOVITSKI, supra note 30,
at 402.
32. Hemophilia is a genetically-based blood disorder that causes a tendency to hemorrhage because the blood has defective coagulating power. The disease is sex-linked, with the
defective genes positioned on the X chromosome. Males carry only one copy of the X chromosome; therefore, if their X chromosome has the defective gene, they will have hemophilia.
Females carry two X chromosomes; if the defective gene is present, it will usually be masked
by a normal gene present on the other X chromosome. Consequently, females rarely have
hemophilia unless both copies of their X chromosome carry the defective gene. Unaffected
"carrier females" can pass the defective gene to their sons, however. Queen Victoria is known
to have been a carrier female; one of her sons was a hemophiliac and three of her daughters
were carriers. Two of the daughters in turn passed their copies of the gene to their offspring.
The next several generations of European royalty had an unusually high incidence of hemophilia. NOVITSKI, supra note 30, at 137-40.
33. Huntingdon's disease is characterized by progressive intellectual deterioration and
spasmodic movements. The condition is caused by a dominant gene that is present at birth but
does not manifest itself until the victim is in his or her late thirties, often after the person has
reproduced and possibly transmitted the gene to offspring. Because the gene is dominant, one
copy is sufficient to trigger the disease. Furthermore, since most affected people carry one copy
of the defective gene and one copy of the normal gene, their offspring stand a 50% chance of
having the defective gene. STEDMAN'S MEDICAL DICTIONARY 1421, 2141 (23rd ed. 1976)
[hereinafter STEDMAN'S 23RD].
34. Tay-Sachs disease is caused by an enzyme deficiency and results in degeneration of
the nervous system. It affects primarily Ashkenazi Jews. About 1 in 35 Ashkenazi Jews carry
one copy of this recessive gene and one copy of the normal gene and are unaffected by the
disease. If two carriers mate, however, their chances of producing an affected child are I in 4.
A relatively simple biochemical test can detect the unaffected carriers because their concentration of the essential enzyme is about 50% of the normal level. NovITSKI, supra note 30, at
192. At least one child with Tay-Sachs disease was conceived by AID. NOVITSKI, supra note
30, at 443.
35. Curie-Cohen, supra note 27, at 585.
36. Curie-Cohen, supra note 27, at 586.
37. See Hummel, supra note 4, at 919.
38. See Hummel, supra note 4, at 919.
39. See Greenblatt, supra note 7, at 359 (advocating that the woman's spouse or other
intimate sexual partner should be screened to reduce "potential confusion regarding . . .
transmission of sexually transmitted diseases via insemination").
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three sources: 1) large-scale commercial sperm banks; 2) research

and teaching hospitals and medical schools; and 3) sperm donors selected by the practitioner.' Initial donor selection criteria vary
among facilities. In the United States, most donors at hospitals and

large clinics are medical students and resident physicians., 1 Larger
commercial sperm banks may advertise for donors, thus sampling a
broader cross-section of a community.' Some facilities have a maximum age requirement, a requirement that donors be married, or a

requirement that the donors restrict sexual contacts to one person.'
Most sperm donation facilities pay the donor a modest fee, ranging
from $25 to $100 per sample."

Having met the initial requirements, a sperm donor usually provides a medical history.' 5 Nature and comprehensiveness of the medical history vary from oral queries regarding history of venereal disease, to detailed written questionnaires and interviews that seek

information about previous infection by a variety of sexually transmitted diseases. "' The presence of genetic disease in the donor, his

immediate family, his children and his ancestors also may be
sought.

7

If a donor has an acceptable medical history, he then contributes a sperm sample. Samples are produced by masturbation, usually
after a three to seven day period of abstinence.' a Samples are analyzed for the presence of minimum quality standards, which include

sperm count, motility, morphology and volume.' 9 Virtually all of the
larger semen donation facilities freeze the samples after the initial
supra note 2, at 77-78; Curie-Cohen, supra note 27, at 586.

40.

See OTA

41.

See Curie-Cohen, supra note 27, at 586.

REPORT,

42. See Andrews, supra note 27, at 636.
43. See J. Selva et al., Genetic Screening for Artificial Insemination by Donor (AID),
29 CLINICAL GENETICS 389, 390 (1986) [hereinafter Selva].
44. See Curie-Cohen, supra note 27, at 587. The profession lacks a consensus as to
whether sperm donors should be paid. Some practitioners believe that donors who are paid too
handsomely will be reluctant to disclose history of infectious or genetic disease. See CurieCohen, supra note 27, at 588; Greenblatt, supra note 7, at 360; Pierre Jalbert et al., Genetic
Aspects of Artificial Insemination with Donor Semen: The French C.E.C.O.S. Guidelines, 33
AM. J. MED. GENETICS 269, 273 (1989) [hereinafter Jalbert]. The acronym, C.E.C.O.S., refers
to the Centres d'Etudes et de Conservation du Sperme Humain (Centers for the Study and
Conservation of Human Sperm). Id. at 269.
45. See Hummel, supra note 4, at 920.
46. See Hummel, supra note 4, at 920-21; Curie-Cohen, supra note 27, at 586.
47. See Hummel, supra note 4, at 920.
48. See Hummel, supra note 4, at 921; see Kantrowitz, supra note 14, at 51.
49. See Hummel, supra note 4, at 921; 1990 Guidelines, supra note 26, at 2S. "Motility" refers to sperm movement; "morphology" refers to shape of the sperm cells. Criteria to
assess semen quality include the following: Volume> 1 ml.; Sperm Motility>60 %; Concentration>50 million per ml.; Morphology of>60% normal forms. 1990 Guidelines, supra note 26,
at 2S.
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analysis and store them until additional tests are completed. 50
After the donor contributes the first sample, he may be subjected to various clinical tests. Many facilities take a blood sample
and test for seropositivity to human immunodeficiency virus (HIV),
the virus that causes A.I.D.S."1 If the result is negative, the donor is

usually tested for HIV again in six months.8 2 Some sperm donation
facilities also test donors' blood for seropositivity to other infectious
diseases.5 3 A few facilities test for biochemical evidence of genetic
disease54 and culture blood cells for use in karyotype analysis.55

50. Hummel, supra note 4, at 921; see Selva, supra note 43, at 390. Prior to freezing,
semen is washed and sperm cells are placed in a 10% glycerol solution. Glycerol, which has
high viscosity, acts like anti-freeze. At temperatures below freezing, it prevents ice crystals
from forming by lowering the freezing point of water. Ice crystals damage living cells because
they puncture and rupture delicate cell membranes. Sherman, supra note 27, at 398-400.
Semen samples are subdivided and placed into small vials, called "straws." Straws hold
0.25-1.0 ml. of semen. Straws are grouped together and placed into larger tubes, called
"canes." Canes are stored in liquid nitrogen at -196"C. Sherman, supra note 27, at 398-406;
New Questions, supra note 14, at 7, 36, 37.
Prior to the mid-1980's, many sperm donation facilities, especially smaller ones, used primarily fresh semen. With the advent of A.I.D.S., however, use of fresh sperm has been virtually discontinued. See Barratt, supra note 1, at 377, 379. Indeed, the principal reason why
sperm is initially frozen today is so that a donor can be tested in the interim for seropositivity
to HIV and perhaps for other infectious diseases. Barratt, supra note I, at 379.
The medical community is divided as to the effect of freezing semen upon conception.
Typically a semen sample shows about a 50% decrease in viability after thawing. Hummel,
supra note 4, at 921. Some researchers and practitioners report a reduced conception rate
using previously frozen sperm, while others report no significant change. Barratt, supra note 1,
at 379. Whatever the true effect on conception, practitioners agree that use of frozen sperm is
now mandatory. Barratt, supra note 1, at 379.
51. But see OTA REPORT, supra note 2, at 37, 68. The report surveyed 1,473 physicians
who perform AID and 15 large sperm banks. Somewhat disturbingly, only 44% of physicians
said they tested for HIV antibody, although all sperm banks did the test. OTA REPORT, supra
note 2, at 37, 68.
52. See Hummel, supra note 4, at 921. Seropositivity to the A.I.D.S. virus may have a
latency period. A person might be infected with the disease for a number of months before a
test would reveal this fact. He would be contagious during the period of seronegativity, and his
semen could carry the virus. The American Fertility Society has, therefore, recommended the
six-month quarantine period on semen donations. See 1990 Guidelines, supra note 26, at 45.
However, recent research suggests that display of seropositivity to the virus may be delayed for
as long as 35 months. David T. Imagawa et al., Human Immunodeficiency Virus Type I
Infection in Homosexual Men Who Remain Seronegative for Prolonged Periods, 320 NEW
ENG. J. MED. 1458, 1460 (1989).
53. See OTA REPORT, supra note 2, at 37, 68.
54. OTA REPORT, supra note 2, at 37-40, 69.
55. See Jalbert, supra note 44, at 271-72; Selva, supra note 43, at 390. Karyotype analysis involves culturing blood lymphocytes and staining them with a dye that is specific for
certain components of DNA. The staining procedure produces a banded appearance of the
chromosomes. Because each normal human chromosome carries a specific set of genes, each
chromosome will exhibit a typical banding pattern. For example, a human female carries
twenty-three pairs of chromosomes. Each pair carries similar genes. When chromosomes are
stained and examined with a microscope, the members of a pair can be located on the basis of
similar banding patterns and morphology. The stained preparation is photographed with a
microscope. Photographic images of each banded chromosome are cut out of the developed
photograph and then arranged by matched pairs on a background. This composition is then re-
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Larger sperm banks may also perform a genitourinary exam, in
which urethral urine is collected for culture of certain other disease
causing organisms."
After six months have passed since the first semen donation, the
sperm donation facility may again test the donor's blood for seropositivity to HIV. 57 If the result is negative after the second test, the
donor may be accepted into a semen donation program.58 During the
program, the donor regularly will contribute samples of his semen
for cryopreservation and ultimately for AID.59
Artificial insemination of the woman is most often effected by
physicians who specialize in treating infertility. 60 Physicians carefully monitor the woman's ovulatory cycle for a few months prior to
AID.6 1 The woman may take drugs that induce ovulation. 61 Inseminations are usually given twice per month.6"
Frozen sperm samples can be shipped across the country by express mail or by delivery services."' Just prior to an AID procedure,
sperm samples are thawed and checked again for viability and
65
motility.
Women report relatively little discomfort when semen is inserted into the reproductive tract. 66 Using a syringe-like instrument,
photographed to provide a "karyotype" for an individual. By comparing the banded homology
of members of a pair of chromosomes, the researcher can detect several types of chromosomal
aberrations. FRANCISCO J. AYALA & JOHN A. KIGER, JR., MODERN GENETICS 588-89 (2d ed.
1984) [hereinafter A & K].
Aberrations include extra copies of chromosomes, e.g., three copies of chromosome 21, a
condition that leads to Down's Syndrome. See id. at 719-21. The researcher also can detect
chromosome structural rearrangements including inversions in the sequence of DNA, translocated pieces of chromosomes and abnormal duplications or deletions of DNA segments. These
structural anomalies can cause infertility in the person who carries them. Furthermore, transmission to offspring can result in infertility in the offspring. Id. at 688-722.
56. See Barratt, supra note 1, at 376; Mayur Chauhan et al., A Protocolfor the Recruitment and Screening of Semen Donors for an Artificial Insemination by Donor Programme, 3 Hum. REPROD. 873, 874-75 (1988).
57. See Barratt, supra note 1, at 377.
58. See Barratt, supra note 1, at 317.
59. See Hummel, supra note 4, at 923.
60. See OTA REPORT, supra note 2, at 15.
61. See Hummel, supra note 4, at 925. Usually the woman keeps basal body temperature (BBT) records for at least two monthly cycles. Ovulation is known to occur just prior to
an increase in BBT. See Hummel, supra note 4, at 925.
62. Women with irregular ovulation patterns may be given clomiphene citrate (Clomed)
or Clomed plus hormonal therapy. Hummel, supra note 4, at 925.
63. Sperm cells survive in a woman's reproductive tract for about 48 hours. Eggs are
receptive to fertilization for about 24 hours. Accordingly, the woman receives AID one to two
days before expected ovulation and on the day of expected ovulation. Hummel, supra note 4,
at 925.
64. See Debate, supra note 14, at 26.
65. See Hummel, supra note 4, at 925.
66. See Stone, supra note 27, at 672. Most patients report no discomfort at all; a few
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the practitioner places 0.1 ml to 0.3 ml of semen into the cervical

canal and also places semen in a plastic insemination cup which is
inserted below the outer cervical canal. 67 The woman remains prone
she may remove the insemination cup affor about twenty minutes;
68
ter about six hours.
Although the conception rate varies among the clinics, conception occurs in 60-70% of women after ten ovulatory cycles. 69 Some
practitioners counsel that after six to ten unsuccessful AID attempts,
the woman should be examined by laparoscopy. 70 After one year of
unsuccessful AID attempts, couples are advised as to other options,
including in vitro fertilization and adoption.7 '
The cost of AID varies with the number of treatment cycles and

with the amount of pre-insemination evaluation that the woman experiences. The average total cost is about $1000.72
Upon achieving a pregnancy, most women do not receive obstetrical care from the AID clinic; rather, they seek care from their own
obstetrician.73 Most women inform their obstetricians that they have
conceived with AID. 7 '

One study showed that the number of AID-induced pregnancies
that successfully reach term is 83.5 %.75 Information about maternal
health during pregnancy and about the health of newborns is surprisingly sparse. The lack of information occurs in part because the link
broken when the
between the woman and the AID clinic is often
7
woman seeks care from her regular physician.

have lower abdominal pain and uterine cramps. See Stone, supra note 27, at 672.
67. See Hummel, supra note 4, at 925.
68. See Hummel, supra note 4, at 925.
69. See Hummel, supra note 4, at 926, Figure 1. The conception rate using fresh semen
was 12% per monthly cycle; the rate was 9.4% when frozen semen was used. See Hummel,
supra note 4, at 926.
70. See Hummel, supra note 4, at 926. See also Stone, supra note 27, at 678.
71. See Hummel, supra note 4, at 926.
72. See OTA REPORT, supra note 2, at 47-49. Cost varies with the recipient's medical
condition and with the number of inseminations required to achieve conception. Most women
spend an average of $309 for preinsemination exams and tests, plus an average of $92 for each
of seven inseminations. See OTA REPORT, supra note 2, at 48.
73. See Curie-Cohen, supra note 27, at 588.
74. Betty Amuzu et al., Pregnancy Outcome, Health of Children, and Family Adjustment after Donor Insemination, 75 OBSTET. & GYNECOL. 899, 902 (1990) [hereinafter
Amuzu].
75. Id. at 900. The researchers found statistically significant correlations between maternal age and spontaneous abortion rate. The rate was 7.6% in women under 25 and 40.9% in
women over 37 years old. Id. at 902.
76. See id. at 902-03. The authors also comment upon the general perception that families wish to maintain confidentiality with respect to their participation in an AID program.
Half of all couples did not tell any of their family or friends of their participation. Id.
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III. Donor Screening Practices
Among the procedures just described, practitioner and semen
donor facility donor screening practices are the most variable." Indeed, the intensity of screening varies from very little to the multi-

stage investigations used by commercial sperm banks and teaching
hospitals.
For example, when Curie-Cohen conducted his study in 1979,

he found that 62% of physicians who performed AID chose medical
students or hospital residents as donors, while other physicians used
university students, hospital personnel and friends as donors. 78 Most
physicians then took donors' medical histories that comprised little

more than a few questions about genetic or common infectious diseases. 79 Curie-Cohen noted, "Beyond the use of this select donor

pool, there is little further screening. 80
Curie-Cohen solicited from respondents their donor rejection
criteria for hereditary diseases. 81 The response from physicians
demonstrated that some doctors had insufficient knowledge of modes
of inheritance. For example, 71.4% of respondents said they would
reject a donor with hemophilia in his family even though the donor
was unaffected.8 2 Genes for hemophilia are carried on the X-chromosome, and males carry only one copy of that chromosome, its "homolog" being the Y chromosome. Thus, if a hemophilia gene is present

in a male, the hemophilia condition will develop. Conversely, if
males do not have hemophilia, they lack the defective gene and
therefore cannot transmit it to their children. 83
Doctors responding to Curie-Cohen's survey also said they

rarely performed biochemical or cytological genetic screening. 84 For
77. See OTA Report, supra note 2, at 67; Andrews, supra note 13, at 636; Greenblatt,
supra note 7, at 358.
78. See Curie-Cohen, supra note 27, at 586; see also OTA REPORT, supra note 2, at 66.
One commentator noted that the predominant use of medical students as donors constitutes a
eugenic decision by AID practitioners to "reproduce themselves." George J. Annas, Fathers
Anonymous: Beyond the Best Interests of the Sperm Donor, 14 FAM. L.Q. 1, 7 (1980) [hereinafter Annas]. Annas wrote that similar selection of one's own "superior genes" would be expected if members of other professions could choose semen donors, e.g., lawyers would probably select law students. Id. Although the point may appear whimsical, further reflection leads
to the query whether AID practitioners are qualified to assess the value of specific genetic
constitutions to our society and species as a whole. Id.
79. See Curie-Cohen, supra note 27, at 586.
80. See Curie-Cohen, supra note 27, at 588. Curie-Cohen noted that only 28.8% of
doctors performed any screening tests other than blood typing.
81. See Curie-Cohen, supra note 27, at 586, 588.
82. See Curie-Cohen, supra note 27, at 588; see hemophilia discussion, supra note 32.
83. See Curie-Cohen, supra note 27, at 588.
84. See Curie-Cohen, supra note 27, at 588.
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example, 94.7 % of doctors said they would reject a carrier of TaySachs disease, but less than 1% said they tested donors for the

gene.8 5 Curie-Cohen's study alarmed the AID community and was
the genesis of numerous symposia, follow-up studies and efforts to

improve screening."
Undoubtedly, the most significant development in efforts to
scrutinize donor screening procedures was the revelation in 1984 that
the HIV virus may be present in semen.8 Only one year later in
Australia, researchers documented the transmission of the HIV virus
via AID to four of eight women who had received sperm from a
donor who later developed seropositivity for the virus. 8 One of the
women subsequently developed A.I.D.S. 89 None of the children
borne by the women had HIV seropositivity, however."' In response,
Australia enacted laws requiring that donors be HIV-negative at the
time of donation and that donors provide a legally binding risk-group
declaration.9 1 Researchers wrote, "The rules now applied in Austra-

lia are stringent; they would have prevented [HIV] transmission
in
92
our patients and should remove the risk for future recipients.
In response to the A.I.D.S. crisis, the American Fertility Society (A.F.S.) published revised donor insemination guidelines in

1986." The guidelines recommended blood tests not only for HIV
virus, but also for several other infectious diseases and certain genetic conditions. 9 The A.F.S. further amended its guidelines in 1988
to include the strong recommendation that all AID procedures be

conducted with previously frozen sperm that had been quarantined
85. See Curie-Cohen, supra note 27, at 588; Tay-Sachs discussion, supra note 34.
86. See CHOICES, supra note 27, at 249; see generally Annas, supra note 78, at 6-9.
87. David Ho et al., HTLV-Il! in the Semen & Blood of a Healthy Homosexual Man,
226 SCIENCE 451 (1984); D. Zagury et al., HTLV-III in Cells Culturedfrom Semen of Two
Patients with AIDS, 226 SCIENCE 449 (1984). The A.I.D.S. virus initially was named human
T-cell lymphotropic virus type III (HTLV-III). Other names included lymphadenopathy-associated virus (LAV) and A.I.D.S. associated retrovirus (ARV). More recently it has been
called human immunodeficiency virus (HIV). Centers for Disease Control, Semen Banking,
Organ and Tissue Transplantation,and HIV Testing 37 MORBIDITY & MORTALITY REP. 57
(1988) [hereinafter CDC 1988]; Centers for Disease Control, ProvisionalPublic Health Service Inter-Agency Recommendationsfor Screening Donated Blood and Plasmafor Antibody
to the Virus Causing Acquired Immunodeficiency Syndrome 34 MORBIDITY & MORTALITY
REP. 1 (1985) [hereinafter CDC 1985].
88. G.J. Stewart et al., Transmission of Human T-Cell Lymphotropic Virus Type III
(HTLV-III) by Artificial Insemination by Donor, ii LANCET 581 (1985).
89. Id. at 582-83.
90. Id.
91. Id. at 583.
92. Id.
93. American Fertility Society, New Guidelinesfor the Use of Semen Donor Insemination, 46 FERTILITY & STERILITY, Supp. 95S (1986) [hereinafter 1986 Guidelines].
94. Id. at 97S-98S.
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for at least six months.95
Despite the efforts of professional societies such as the A.F.S.,
physician-practitioners of AID were slow to perceive the need for
improved donor screening practices. 96 In 1987, the Congressional Office of Technology Assessment (O.T.A.) conducted a large survey of
the donor screening practices of 1,473 AID physicians and 15 sperm

banks.97 The study results disclosed that only 48 % of the physicians
who regularly practiced AID required special screening to detect genetic disorders in high-risk donors." Although nearly ten years had
passed since Curie-Cohen's 1979 study, the O.T.A. study nevertheless demonstrated many physicians' continued unfamiliarity with

fundamental genetic disease transmission patterns.99 Authors of the
O.T.A. report concluded that, "Although 44% of physicians doing
insemination said they test semen for HIV antibody, only about one-

fourth test for syphilis, gonorrhea, hepatitis, or chlamydial infection."' 100 In contrast to the physicians, all fifteen sperm banks said
they test donors for sexually transmitted diseases, including HIV seropositivity. 10 During the past five years, several active AID re-

searchers and practitioners have presented additional evidence demonstrating that numerous infectious diseases are transmitted via

AID." 2 Other researchers have examined the donor screening process with respect to genetic defects and tests for genetic defects. 10 3
Practitioners and commentators are also proclaiming, in increasing
numbers, the need to keep more complete records of donor medical
histories. 04 The following discussion examines each of these three

aspects of the donor screening process.
95. American Fertility Society, Revised New Guidelines for the Use of Semen Donor
Insemination, 49 FERTILITY & STERILITY 211 (1988) [hereinafter 1988 Revision].
96. See Barratt, supra note 1, at 375.
97. See generally OTA REPORT, supra note 2.
98. See OTA REPORT, supra note 2, at 9.
99. See Barratt, supra note 1, at 375.
100. Charles Marwick, Artificial Insemination Faces Regulation, Testing of Donor Semen, Other Measures, 260 J.A.M.A. 1339, 1340 (1988).
101. Id.
102. See generally Barratt, supra note 1; Christopher L.R. Barratt et al., Screening
Donorsfor Sexually Transmitted Disease in Donor Insemination Clinics in the United Kingdom. A Survey, 96 BRIT. J. OBSTET. & GYNECOL. 461 (1989); Greenblatt, supra note 7; Hummel, supra note 4.
103. See M. del Mar Perez et al., Karyotype Screening of Potential Sperm Donorsfor
Artificial Insemination, 5 HuM. REPROD. 282 (1990); Federation CECOS, Mattei & Le
Marec, Genetic Aspects of Artificial Insemination by Donor (AID). Indications, Surveillance
& Results, 23 CLINICAL GENETICS 132 (1983); Matthews, supra note 10 at 648; Selva, supra
note 43, at 389.
104. See Andrews, supra note 13, at 639; Curie-Cohen, supra note 27, at 588-89.
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A.

Screening for Sexually Transmitted Diseases

With respect to sexually transmitted diseases (STD's), justification for donor screening includes not only the obvious potential reduction in disease transmission, but also the accompanying effects
that many of these diseases have on the reproductive tracts of the
recipient women, on fetal ontogeny, and on neonatal health. 10 5 Ironically, in their efforts to circumvent male infertility, practitioners
may have contributed to female infertility by artificially inseminating women with unscreened donor semen carrying STD's. Recent
literature identifies about twelve sexually transmitted pathogens for
which semen donors should be screened.1 06 These organisms include
viruses, mycoplasmas, bacteria and protozoans. Appendix A presents
a list of these pathogens and the following discussion briefly summarizes the nature and effects of each one.
1.

Viral Infections.-

a. HIV.-This causative agent of A.I.D.S. can be detected using the ELISA antibody test.10 It is essential to screen all
semen donors because the disease is potentially fatal.10 8 Men belonging to high-risk groups should be excluded as donors.10 9
b. Hepatitis-B.-Risks include maternal hepatitis-B, in
utero infection of the fetus, pre-mature delivery and transmission to
the child during birth. 1 Transmission via AID has been reported.1 '
Semen antibodies to the virus can be detected easily and inexpensively.' 12 The donor should be rejected if the test is positive. 1
c. Cytomegalovirus (CMV).-This herpes-like, virus may
be asymptomatic in carrier males."" Prevalence varies in human
populations but is generally high compared to other STD's. For ex105. See Greenblatt, supra note 7, at 351-58.
106. See Christopher L.R. Barratt et al., Screening Donorsfor Sexually Transmitted
Disease in Donor Insemination Clinics in the U.K. A Survey, 96 BRIT. J. OBSTET. & GYNECOL.
461, 462-65 (1989); Greenblatt, supra note 7, at 352-58; Hummel, supra note 4, at 921-25.
Pathogens are disease-causing organisms. STEDMAN'S 23RD, supra note 33, at 104.
107. See Hummel, supra note 4, at 923.
108. See Hummel, supra note 4, at 923.
109. See Greenblatt, supra note 7, at 354; Hummel, supra note 4, at 933.
110. See Greenblatt, supra note 7, at 352.
111. William R. Berry et al., Transmissionof Hepatitis-B Virus by Artificial Insemination, 257 J.A.M.A. 1079 (1987).
112. See Greenblatt, supra note 7, at 352.
113. See Hummel, supra note 4, at 922.
114. See Greenblatt, supra note 7, at 352.
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ample, in San Francisco, 36% of male blood donors 18-29 years old
carried the virus. 115 CMV produces severe congenital defects in fetuses and newborns, including brain damage, deafness, visual defects
and even death." 6 Further, CMV infection in early pregnancy
"might well represent the major preventable cause of birth defects in
the offspring resulting from therapeutic insemination by donor."''117
Serum antibody tests can detect CMV. 1 8 Donors should be rejected
if seropositivity is confirmed by subsequent urine or semen
cultures." 9
d. Herpes simplex.-Acquisition of primary genital
herpes or type 2 herpes at conception includes risks of transmission
of the disease to the recipient woman, cervical carcinoma associated
with type 2 herpes, 20 fetal abortion, congenital infection, and transmission to the child at birth.12' Herpes has been transmitted via
AID. 22 To date, no reliable serological or semen screening tests are
available. 2 3 Therefore, semen donation facilities should exclude potential donors who have a history of genital herpes, as well as appar24
ently unaffected donors whose sexual partners have the disease.
e. Human papilloma virus (HPV).-This causative agent
of genital warts is frequently found in the male urethra. 25 HPV has
been implicated as the cause of cervical dysplasia and cancer of the
vulva.' 26 Reportedly, the virus can be transmitted to the newborn at
birth and subsequently causes anal and penile infections. 1 27 No readily available screening method currently is available; thus, all potential semen donors with a history of genital warts should be
28
rejected.
115. See Greenblatt, supra note 7, at 352.
116. See Hummel, supra note 4, at 922.
117. See Greenblatt, supra note 7, at 353.
118. See Hummel, supra note 4, at 922.
119. See Hummel, supra note 4, at 922.
120. See Hummel, supra note 4, at 922.
121. See Greenblatt, supra note 7, at 354.
122. Donald E. Moore et al., Transmission of Genital Herpes by Donor Insemination,
261 J.A.M.A. 3441 (1989).

123. See Hummel, supra note 4, at 922.
124. See Hummel, supra note 4, at 923.
125.
126.

See Hummel, supra note 4, at 923.
See Hummel, supra note 4, at 923. Cervical dysplasia is abnormal development of

cervical tissue. It may progress to cancer. STEDMAN'S 23RD, supra note 33, at 433.
127. See Greenblatt, supra note 7, at 355.
128. See Hummel, supra note 4, at 923; Greenblatt, supra note 7, at 355.
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2. Mycoplasma Infections: 9 Mycoplasma hominis and
Ureaplasma urealyticum.-Both frequently are present in the male
urethra. One study found Ureaplasma urealyticum in 58% and
Mycoplasrna hominis in 42% of 62 asymptomatic men. 3 0 Researchers are unsure whether the organism is pathogenic or commensal.' 3'

Ureaplasma urealyticum is associated in males with urethritis.13 2 In
females the organism is associated with genitourinary infections,
spontaneous abortions, stillbirths and low birth weights."33 More research is required to provide dispositive proof of the connection between these organisms and the affected conditions. Because the organisms are so prevalent in potential donors, exclusion on this basis
could reduce the available donor pool significantly.3 4 One researcher
recommends culturing semen and treating the donor if a positive result occurs.'3 If repeat cultures are negative, the man could be an
acceptable donor. 36
3. Bacterial Infections.a. Chlamydia trachomatis.-This bacterium has been
transmitted via AID and is an increasingly common cause of pelvic
inflammatory disease (PID) in women. 13 PID is a leading cause of
female infertility. 3 8 In males the organism is associated with urethritis and epididymitis. 39 Approximately two-thirds of newborns
exposed to Chlamydia at birth display infections of the eye or eyelids, nose and throat, and rectum or vagina;'40 Chlamydia also is
associated with low infant birth weight, pre-term delivery and rupture of fetal membranes.14 ' Potential semen donors can be tested in
several ways for this bacterium and tests should be repeated every
129. Mycoplasmas are non-motile bacteria-like organisms that are barely visible with a
light microscope. They require urea and cholesterol for growth. STEDMAN'S MEDICAL DicTIONARY 24TH ED. 915, 1517 (1982).
130. See Greenblatt, supra note 7, at 357; King K. Holmes et. al., Etiology of Nongonococcal Urethritis, 292 NEW ENG. J. MED. 1199, 1201 (1975).
131. See Hummel, supra note 4, at 924. Pathogenic organisms cause disease. Commensal organisms live together without harm to each other, and one or both derive benefit from the
association. STEDMAN'S 23RD, supra note 33, at 302.
132. See Greenblatt, supra note 7, at 357.
133. See Greenblatt, supra note 7, at 357.
134. See Hummel, supra note 4, at 924.
135. See Hummel, supra note 4, at 924.
136. See Hummel, supra note 4, at 924.
137. Theodore C. Nagel et al., Transmission ofCHLAMYDIA TRACHOMATIS by Artificial
Insemination, 46 FERTILITY & STERILITY 959, 960 (1986).
138. See Greenblatt, supra note 7, at 356.
139. See Greenblatt, supra note 7, at 356.
140. See Greenblatt, supra note 7, at 356.
141. See Greenblatt, supra note 7, at 356.
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six months.' 42 The disease can be treated, and if test results are negative after the donor is retested, he can be admitted to a semen do143
nation program.
b. Neisseria gonorrhoeae.-This organism causes gonor144
rhea, which, like Chlamydia infection, is increasing in frequency.
In males the disease can be asymptomatic; 145 in females it has resulted in cervicitis, PID, and gonococcal arthritis. 146 The organism
may cause several adverse fetal effects, including spontaneous abortion, stillbirth and growth retardation."17 The newborn may exhibit
eye, throat and anal infections as well as meningitis." 8 Infection in
men is readily detectable with semen and urethral fluid culture." 9
Men who test positive can be treated and re-tested; if the second test
results are negative, the donors can be admitted to an AID program. 150 Testing should be repeated every six months for all
donors.' 51
c. Treponema pallidum.-This bacterium causes syphilis.
Transmission via AID is not yet reported, despite recent increases in
the incidence of the disease. 52 Easily detected with serological
screening, the disease is treatable with antibiotic therapy. 153 Donors
5
should be re-tested each year.1 '
d. Group B Streptococcus.-This organism causes a variety of infections in women, including PID. 55 In pregnant women,
the disease has caused various adverse effects, including premature
labor and neonatal sepsis.' 56 Although researchers have documented
Group B Streptococcus infection following AID, 57 it is unclear
whether the organism can establish itself in the female reproductive
142.
143.
144.
145.

See
See
See
See

Hummel, supra note 4, at 921.
Hummel, supra note 4, at 921.
Greenblatt, supra note 7, at 355.
Greenblatt, supra note 7, at 355.

146. See Greenblatt, supra note 7, at 355-56.
147.
148.
149.
150.
151.
152.
153.
154.
155.

See
See
See
See
See
See
See
See
See

156.

See Hummel, supra note 4, at 924.

Greenblatt, supra note 7, at 356.
Greenblatt, supra note 7, at 356.
Greenblatt, supra note 7, at 36; Hummel, supra note 4, at 922.
Hummel, supra note 4, at 922.
Hummel, supra note 4, at 922.
Hummel, supra note 4, at 924.
Greenblatt, supra note 7, at 357.
Hummel, supra note 4, at 925.
Hummel, supra note 4, at 924.

157. S.J. Kleegman, Therapeutic Donor Insemination, 31 CONN.MED. 705, 711 (1967)
[hereinafter Kleegman].
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tract subsequent to an AID procedure.15 8 Some AID programs use
semen culture to screen all donors for this organism. 159 Potential donors who test positive can be treated with antibiotic therapy and can
be admitted to an AID program after a negative culture. 6 0
4. Protozoan Infection: Trichomonas vaginalis.-While men
with urethral infection usually exhibit no symptoms,' 1 symptoms in
women are more pronounced. 62 The disease has not been associated
with major ill effects on the developing fetus, but it may be transmitted to the newborn.' 6 3 Infection following AID has been reported in
two cases."' Semen of potential donors can be easily examined for
presence of the organism by making a simple wet mount slide preparation. 16 5 The disease is treatable and donors can be accepted into an
AID program after a negative culture.' 6 6
The list of pathogenic organisms presented above may appear
comprehensive, but researchers are quick to caution that they have
not conducted any large controlled studies to determine the true frequency of transmission via AID.' 6 7 Although it may be argued that
screening requirements would be premature without sound epidemiological data, 6' there are the individual documented reports of transmission via AID. Obtaining data from controlled experiments is ethically problematic because ideal experimental design would involve
purposeful infection of large numbers of individuals, as well as nontreatment for the control group. It would be more ethically unsound,
however, to fail to screen 'donors and therefore facilitate transmission
of these diseases to recipients and their children. A donor screening
program for STD's also enables practitioners to fulfill their duty to
safeguard the donor, because donors with STD's can be successfully
treated or advised on their prognoses.
A few studies recently have been conducted on the incidence of
STD's in donors at large-scale semen banking facilities. In one
study, researchers found urethral pathogens in one-third of thirty-six
158.
159.
160.
161.

See
See
See
See

162.
163.
164.
165.
166.
167.
168.

AMERICAN MEDICAL ASSOCIATION FAMILY MEDICAL GUIDE

Hummel,
Hummel,
Hummel,
Hummel,

supra
supra
supra
supra

note
note
note
note

4,
4,
4,
4,

at
at
at
at

924.
924.
925.
925.

615 (1987).
See Greenblatt, supra note 7, at 357-58.
See Kleegman, supra note 157, at 711.
See Hummel, supra note 4, at 925.
See Hummel, supra note 4, at 925.
See Barratt, supra note 1, at 376.
Epidemiology is the study of the spread and prevalence of disease in a population.
STEDMAN'S 23RD, supra note 33, at 470-71.
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donor applicants.' 69 A second study in Belgium, in which 237 donors
were screened for pathogens, showed that 47 % of donors were infected with one or more pathogenic micro-organisms, including
Chlamydia (6.3%), Mycoplasma (4.6%), Ureaplasma (35.9%) and
CMV (0.4% ).170 Some donors' semen had already been used for
AID. 7 ' Authors of the study concluded unequivocally that "the ex-

clusion of microbiological contamination with sexually communicable micro-organisms before insemination [was] indicated. 172 Numerous other authors also have called for mandatory donor selection
and screening procedures." 3
B.

Screeningfor Genetic Defects

Most AID programs permit a couple to match certain physical
characteristics of the husband with those of the donor.17 4 Characteristics include height, hair color, eye color, body type and race. 175 In
addition, most AID clinics match blood type and Rh-factor. 17
A few sperm banks limit their donor pool to Nobel laureates,
distinguished scientists, authors and sports figures. 77 Many geneticists are skeptical of the heritability of traits sought by the recipients, such as creativity, physical prowess and capacity to make quantum intellectual leaps.'7 8 To the degree that these traits are
169. See Barratt, supra note 1, at 376.
170. K.H. Tjiam et al., Sexually Communicated Micro-organisms in Human Semen
Samples to be Used for ArtificialInsemination by Donor, 63 GENITOURINARY MED. 116, 117
(1987).
171. Id. at 116, 118.
172. Id. at 116.
173. See Barratt, supra note 1, at 376; see also Christopher L.R. Barratt et al., Screening Donors for Sexually Transmitted Disease in Donor Insemination Clinics in the United
Kingdom, 96 BRIT. J. OBSTET. & GYNECOL. 461, 464 (1989); Mayur Chauhan, et al., A Protocol for the Recruitment and Screening of Semen Donors for an Artificial Insemination by
Donor Programme, 3 HuM. REPROD. 873, 375-76 (1988); E.F. Monteiro et al., Sexually
Transinitted Disease in Potential Semen Donors, 295 BRIT. MED. J. 418, 418 (1987).
174. The physical or biochemical manifestation of a gene is termed the "phenotype." A
& K, supra note 55, at G-14. The process of matching similar characteristics of husband and
donor is called phenotypic matching. Hummel, supra note 4, at 925. Genetic constitution, i.e.,
which genes are actually present, is termed the "genotype." A & K, supra note 55, at G-7.
175. See Hummel, supra note 4, at 925.
176. See Hummel, supra note 4, at 925.
177. See NovIrsKI, supra note 30, at 443. The idea allegedly was advanced by a geneticist, H.J. Muller, in the 1930's. Novitski states:
The common example advanced in favor of the propagation of such genes is
given by the case of Albert Einstein: How many women, faced with the necessity
of having a child by artificial insemination by donor, might prefer that he be the
father, rather than some unknown and impecunious medical student? Or might
a woman prefer to have an offspring by such a distinguished man rather than by
her relatively untalented husband?
NoviTsri, supra note 30, at 443.
178. See NovrSKI, supra note 30, at 443. Heritability is the degree to which a trait has
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heritable, they are transmitted by complex polygenic mechanisms; 79
furthermore, there is a strong environmental, or non-genetic, component to their expression.180

Genetic variation is normal in human populations. Indeed, it is
the raw material of natural selection and evolutionary change.' 8 ' Genetic variation usually arises by spontaneous mutations, which may

increase, decrease or have no effect on the fitness of the individual
82
who carries them.'
Deleterious mutations involve single genes, closely situated
small groups of genes, chromosomal rearrangements and chromo-

somal duplications and deletions. 183 Effects of single gene mutations
range from minor metabolic disturbances to severe disruption of
growth and development.18 Chromosomal aberrations may cause in-

fertility, mental retardation and abortion.' 85
Genetic considerations for artificial insemination include the
type and intensity of screening for both the donor and the recipient.

Three levels of screening occur. First, and most important, is the
taking of a genetic history.' 88 The second level includes biochemical
testing for the presence of defects or marker genes that indirectly
indicate the presence of a deleterious gene, such as the gene for

Huntingdon's disease. 8 7 Third, some sperm donation facilities conduct karyotype analysis.'
1. Genetic History.-There is no consensus among experts as
to how comprehensive the genetic history of the donor and the recipa genetic, rather than environmental basis. A & K, supra note 55, at G-8.
179. See NoviTsKI. supra note 30, at 443.
180. Statistically speaking, even Albert Einstein, Leonard Bernstein, H.J. Muller, and
Babe Ruth carried deleterious genes. If these people had contributed more than their fair
share of genes to succeeding generations via AID, there would be a risk of increasing the
frequency of these deleterious genes in the population. NovITsKI, supra note 30, at 443.
Theodosius Dobzhansky, an evolutionary geneticist and the object of the author's deep
admiration and respect, had this opinion:
Muller's implied assumption that there is, or can be, the ideal human genotype
which it is desirable to bestow on everybody, is not only unappealing but almost
certainly wrong-it is human diversity that acted as a leaven of creative effort in
the past and will so act in the future.
Annas, supra note 78, at 4 (quoting Theodosius Dobzhansky).
181. See A & K, supra note 55, at 779-80.
182. See A & K, supra note 55, at 678-85, 800-01.
183. See NOVITSKI, supra note 30, at 662-730.
184. See NOVITSKI, supra note 30, at 92-108.
185. See NoVITSKl, supra note 30, at 145-177.
186. See Jalbert, supra note 44, at 269-72.
187.

See Matthews, supra note 10, at 649. But see Jalbert, supra note 44, at 271.

188. See Jalbert, supra note 44, at 271.
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ient should be. 18 9 The principal reason for this is that most people, if
questioned at length, will reveal conditions in themselves, their immediate relatives and their ancestors, which could be indicative of
genetic defects. 9 ' Therefore, a sperm donation facility must weigh
the ideal of using donors who are free from all potential disorders
against the possibility that too many potential donors will be rejected
if the level of scrutiny is too harsh. 91 The decision to accept a donor
thus involves a certain degree of risk. 192 One researcher stated, "If
we cannot but take certain risks in choosing donors, the important
thing, however, is to avoid matching a donor displaying a pathologic
[family] trait with a recipient with the same risk in her family." 9 '
The American Fertility Society (A.F.S.) recommends a minimum genetic history screen for potential semen donors.194 The guidelines emphasize two levels of screening: (1) the presence of deleterious genes in the donor, and (2) the presence of defects in the donor's
parents and offspring. 95 The A.F.S. guidelines recommend exclusion
of potential donors who evidence major congenital malformations
such as spina bifida, cleft palate, heart defects, hip dislocation and
clubfoot.' 96 Also recommended for exclusion are donors who exhibit
"nontrivial" single-gene mutations, such as albinism, hemophilia, hemoglobin disorders and Huntingdon's disease. 91 Carriers of deleterious genes that occur in particular ethnic groups should also be ex' In addition, potential donors should not have
cluded. 98
any disease
known to occur in families, e.g., asthma, juvenile diabetes, epilepsy,
psychoses or rheumatoid arthritis. 199
2. Biochemical and Karyotypic Screening.-Authorities differ
as to whether biochemical or karyotypic analysis should be performed on the donor.2 0 With respect to karyotypic screening, the
189. See Matthews, supra note 10, at 648.
190. See Matthews, supra note 10, at 652.
191. See Selva, supra note 43, at 389.
192. See Selva, supra note 43, at 389. The risk factor is more important for genetic
defects than it is for infectious diseases because many recessive genetic defects are not as
easily detected as are infectious organisms. In the absence of sequencing the DNA of all people, probability determines whether a person carries a deleterious gene. It also is determined
by the frequency of the gene in the population.
193. See Selva, supra note 43, at 389.
194. See 1990 Guidelines, supra note 26, at 8S.
195. 1990 Guidelines, supra note 26, at 8S.
196. 1990 Guidelines, supra note 26, at 8S.
197. 1990 Guidelines, supra note 26, at 8S; see also supra note 33.

198.

1990 Guidelines, supra note 26, at 8S.

199.

1990 Guidelines, supra note 26, at 8S.

200. See Jalbert, supra note 44, at 271; Matthews, supra note 10, at 652-53; Selva,
supra note 43, at 394. Contra M. del Mar Perez et al., Karyotype Screening of Potential
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A.F.S. advises practitioners to balance the need to screen with "how
small a risk one can afford to ignore. "201 Other guidelines advise that
a donor should not carry "chromosomal rearrangements that may
' 20
result in unbalanced gametes. 1
The donor's parents or offspring should not exhibit any of the
congenital defects discussed above, nor should they exhibit any of
the single-gene or chromosomal defects. 2 3 Furthermore, if the genetic history discloses evidence in second degree relatives 204 of diseases such as major psychoses, epilepsy and juvenile diabetes, the
donor should possibly be rejected.20 5
In France, sperm banks are organized and administered "on a
national basis,"2 0 6 and collectively called the C.E.C.O.S. Federation. °7 In 1989 C.E.C.O.S. published its guidelines for genetic
screening. 20 8 Like the A.F.S. guidelines, C.E.C.O.S. emphasizes that
a detailed genetic history should be taken, 20 9 but C.E.C.O.S. also
suggests that the person taking the history should be a physician
trained in genetic counseling.2 10 Like the A.F.S. guidelines, the
C.E.C.O.S. guidelines suggest close scrutiny for genetic conditions
that occur in the donor, 21 and diseases that justify exclusion are essentially the same as those recommended by the A.F.S.2 12 Significantly, however, C.E.C.O.S. requires a karyotype analysis.21 3
The list of deleterious genetic conditions for which both organizations recommend screening may appear too exclusionary. However, C.E.C.O.S. has collected data on its donor rejection rates using
these criteria, and the rates are surprisingly low. One C.E.C.O.S.
AID center rejected outright only 3 % of potential donors based on
genetic history and only another 3 % on karyotype analysis.2 14
3.

Record Keeping.-Curie-Cohen found in his 1979 study

Semen Donors for Artificial Insemination, 5 HUM. REPROD. 282, 284 (1990).
201. See 1990 Guidelines, supra note 26, at 8S.
202. 1990 Guidelines, supra note 26, at 8S. Gametes are eggs or sperms.
203. 1990 Guidelines, supra note 26, at 9S.
204. Second degree relatives include siblings, grand parents and grandchildren. 1990
Guidelines, supra note 26, at 9S.
205. 1990 Guidelines, supra note 26, at 9S.
206. See Jalbert, supra note 44, at 273.
207. See Jalbert, supra note 44, at 269.
208. Jalbert, supra note 44, at 271.
209. See Jalbert, supra note 44, at 271.
210. See Jalbert, supra note 44, at 271.
211. See Jalbert, supra note 44, at 271.
212. See Jalbert, supra note 44, at 271.
213. See Jalbert, supra note 44, at 271.
214. See Jalbert, supra note 44, at 271.
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that 70% of physicians failed to keep permanent medical records on
donors.21 Physicians felt they must insulate donors from possible financial liability for the child, as well as from future contacts with
either the recipient or her child. 216 Since 1979, most states 21have
en7
acted statutes that relieve donors of any financial liability.
Children conceived with AID face several potential disadvantages compared to children conceived by sexual intercourse. First,
many AID children never will be told by their parents that their
biological fathers were anonymous donors.218 In the event the child
requires tissue matching for procedures such as tissue or organ
transplants, the child will be unable to request the donor's assistance
if no records exist. Second, if children encounter medical problems
as a result of a genetic defect or infection, they or their parents may
be unable to contact the donor so that the donor can be treated or
excluded from further AID participation.21 9
The A.F.S. guidelines recommend that confidential, permanent
records be kept for donors. 22 0 The record should comprise genetic
and other non-identifying information and should be available to recipients or their offspring on an anonymous basis.2 21 Record keeping
should also include notation of how many times a donor's sperm has
been used for AID. 22 Especially in small communities, if a single
donor is involved in a large number of AID procedures, there is a
higher probability that half-siblings will marry without knowledge of
their relationship.223 Consanguineous matings can increase the expression of harmful recessive genes. The A.F.S. guidelines recommend that a donor be limited to ten pregnancies.22
IV.

Rationale for Change

A.

The Status Quo
The most recent broad-based attempt to assess the status quo

215. See Andrews, supra note 13, at 639.
216. See Andrews, supra note 13, at 639.
217. See Andrews, supra note 13, at 639.
218. See Amuzu, supra note 74, at 903. Of 594 respondents to the authors' survey, 47%
said they would not tell their children that they had been conceived with AID. Thirteen percent said they would definitely disclose their children's heritage; the rest were ambivalent or
undecided. Amuzu, supra note 74, at 903.
219. See Andrews, supra note 13, at 638-39.

220. See 1990 Guidelines, supra note 26, at 9S.
221.
222.
223.
224.

See
See
See
See

1990 Guidelines, supra note 26, at 9S.
Andrews, supra note 13, at 638.
Andrews, supra note 13, at 638.
1990 Guidelines, supra note 26, at 4S.
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with respect to AID practices was the 1987 O.T.A. study.22 5 This
study disclosed widespread inattention of physicians to screening
practices for both infectious and genetic diseases. 22 6 The study
sparked renewed efforts by the A.F.S. and by individual researchers
to provide advisory guidelines to physicians and sperm banks.227 Beyond 1987, no data are available to assess the status quo. Efforts by
the A.F.S. and by individual researchers probably have led to some
improvement in screening, as has the ever-increasing public awareness of the A.I.D.S. crisis.
Of the three types of facilities that receive semen donations,
commercial sperm banks and larger clinics and hospitals exhibit the
most comprehensive screening practices, as indicated by Curie-Cohen's 1979 study and by the 1987 O.T.A. Report.228 Indirect evidence of good practices is provided by the absence of fully adjudicated cases involving the negligence or malpractice of AID
practitioners or sperm
donation facilities. The New York City
"wrong sperm" case229 certainly has generated much attention, but
information disclosed by the press indicates generally sound record
keeping and sample identification procedures by the sperm bank.230
In the event that the woman does prove negligence, her case may be
an example of a situation where the sperm bank took the appropriate
measures to label samples properly, but someone farther along the
distribution chain mislabelled or mistook another donor's sperm sample for that of her husband. For this woman and others in similar
situations, the law provides relief through individual tort actions.
The current status of donor screening practices in small clinics
and individual practitioners is unknown. Both Curie-Cohen and the
O.T.A. Report point out that the smaller clinics most often fail to
comply with federal recommendations and professional guidelines.23'
Therefore, effective regulation of donor screening procedures would
necessarily have to include these small-scale facilities.
The lack of fully adjudicated tort claims involving sperm donor
screening practices provides some evidence that the current system
225.

See generally OTA REPORT, supra note 2.

226. See OTA

REPORT,

supra note 2, at 10; see also notes 93-104 and accompanying

text.
227. See generally 1988 Revision, supra note 95; 1990 Guidelines, supra note 23; Barratt, supra note 1; Hummel, supra note 4.
228. OTA REPORT, supra note 2, at 9; Curie-Cohen, supra note 27, at 589; Debate,
supra note 14, at 26.
229. See supra notes 14-23 and accompanying text.
230. See Debate, supra note 14, at 3.
231. See OTA REPORT, supra note 2, at 9; Curie-Cohen, supra note 27, at 585.
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works reasonably well. However, no data exist as to how many
claims are settled prior to trial. It is also uncertain how many cases
have had their records sealed by courts, as has happened in the New
York City case.
A second argument for maintaining the status quo is that most
larger commercial sperm banks and clinics already follow the 1990
A.F.S. Guidelines, and many even screen more intensively than what
is recommended.282 Furthermore, voluntary compliance enables commercial operations to reduce their risks, yet still derive an economic
2 33
benefit. This keeps the cost to consumers relatively low.
The current status quo also gives states wide latitude as to what
aspects of donor insemination, if any, should be regulated. States can
also tailor any regulations to local conditions. In turn, there is less
governmental intrusion in family and donor privacy.
If all donor screening practices were similar to those of large
sperm banks, there would be little need for governmental intervention, except perhaps for occasional updates on recommended procedures. Unfortunately, smaller facilities' practices often do not meet
recommended standards. 23 4 This increases the risk that infectious
and genetic diseases will be transmitted to recipients and their offspring. Some of the sexually transmitted diseases, notably A.I.D.S.,
are incurable and almost certainly result in death. Other diseases
have the potential to infect or scar the woman's reproductive tract
and cause infertility. 5 In this respect, poor screening practices can
thwart one of the woman's most important objectives, which is to
conceive. The woman's reasonable expectations of having a healthy
child also can be lessened because many sexually transmitted diseases impair normal fetal development and cause morbidity in the
newborn child.23 6 The specter of sexually transmitted diseases also
extends to the woman's spouse or other intimate partner.
Among the states, less than half regulate donor screening in any
respect. Even if a state does require screening, a recipient could seek
AID in another state that lacks screening requirements. Furthermore, many sperm banks offer "mail order" services, 23 and an AID
clinic could purchase samples from a bank located in a state that
232. See OTA REPORT, supra note 2, at 3.
233. See CHOICES, supra note 27, at 141, Table 8.1. Semen samples cost about $40
each. CHOICES, supra note 27, at 141, Table 8.1.
234. See CHOICES, supra note 27, at 141, Table 8.1.
235. See supra notes 137-151 and accompanying text.
236. See supra notes 105-173 and accompanying text. "Morbidity" refers to a diseased
condition. AMERICAN HERITAGE DICTIONARY 459 (Paperback ed. 1976).
237. See Debate, supra note 14, at 26.
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does not have screening requirements, especially if banks in non-regulated states offer lower prices.
The risks associated with sexually transmitted diseases and genetic disorders are too great to leave donor screening a matter of
private discretion or individual state regulation. The federal government must increase its role by regulating screening for sexually
transmitted diseases. The ultimate objective should be to maximize
the best interests of the recipient and her child.
B.

Previous Role of the State in Donor Screening Procedures

1. Recommendations.-To date, the voluntary guidelines created by private societies such as the A.F.S. offer the most guidance
for practitioners. 238 The American Society of Tissue Banks also publishes standards which include screening for STD's by tissue and organ banks.23 9
The federal government has occasionally issued recommendations regarding donor screening practices. In 1985, The Centers for
Disease Control (CDC) recommended that individuals likely to be
infected with HIV should refrain from donating blood. 40 Similarly,
one of the U.S. Public Health Service's objectives in its plan to prevent and control A.I.D.S. was to "[e]ncourage testing of donors of
organs, tissues, cells and semen for antibody to [HIV]. ' 24'1 In 1985,
the CDC also recommended that all donated semen be tested for
antibody to HIV.2 41 In 1986, the Public Health Service urged that
the 1985 CDC recommendations concerning semen donor testing be
made mandatory. 4" After researchers revealed that a seropositive
reaction to HIV can be delayed for several months, the CDC issued
recommendations that semen donors' blood be tested for HIV; that
donor semen be frozen for at least six months; and afterward, that
244
donors be tested again for HIV.
238. See Debate, supra note 14, at 26.
239. AMERICAN ASSOCIATION OF TISSUE BANKS, STANDARDS OF TISSUE BANKING 30
(1987).
240. See CDC 1985, supra note 87, at 3.
241. U.S. Public Health Service, Public Health Service Plan for the Prevention and
Control of Acquired Immune Deficiency Syndrome (AIDS), 100 PUB. HEALTH REP. 453, 454

(1985).
242.

Centers for Disease Control, Testing Donors of Organs, Tissues, and Semen for

Antibody to Human T-Lymphotropic Virus Type IlI/Lymphadenopathy-Associated Virus, 34
MORBIDITY & MORTALITY REP. 294, 294 (1985).
243. U.S. Public Health Service, Coolfont Report: A PHS Plan for Prevention and
Control of AIDS and the AIDS Virus, 101 PUB. HEALTH REP. 341, 347 (1986).
244.

See CDC 1988, supra note 87, at 63.
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2. Regulations.-States derive from the Tenth Amendment
the power to protect the health and safety of the public. 4 5 State law
regulates most public health measures and all licensing of medical
personnel and facilities. 246 Therefore, it is well within the authority
of states to license sperm banks and require testing of potential semen donors for STD's.24 7 Twenty-three states have requirements for
testing semen donors for STD's. The following discussion divides
these twenty-three states into three groups.
a. No Testing Required but Other Provisions May Apply.-In New York, a health care provider or facility that procures,
processes or distributes semen need not test semen for HIV.2 "8 Even
if the provider or facility tests for HIV, it need not inform the donor. 24 9 If the provider or facility does inform donors of positive test
results, the facility must provide post-test counseling.250 Iowa does
not require that a donor be notified or counseled if tests are conducted on semen. 25 ' In Washington, results of HIV tests normally
are kept confidential, but sperm banks may :receive information
about semen donors' treatment for A.I.D.S. or other STD's.252 West
Virginia permits physicians to test donors, recipients or the semen
itself for HIV to the extent a test is necessary to assure acceptability
of the donor, the recipient or the semen.253 Idaho encourages sperm
donation facilities to use all "reasonable means" to detect HIV in
potential donors.254 Oregon does not require any testing, but prohibits any donor who knows he has a genetic disease or venereal disease
from donating.255 California and Texas place a similar duty on the
donor, imposing criminal penalties on a donor who contributes semen
256
knowing that he has A.I.D.S. or is HIV positive.
b. Required Testing for HIV.-Rhde Island requires
245.

U.S. CONST. art. X.
CHOICES, supra note 27, at 172.
247. Tauyna Lovell Banks & Rogert R. McFadden, Rush to Judgment: HIV Test Reliability and Screening, 23 TULSA L.J. 1, 19 (1987) [hereinafter Banks].
248. See N.Y. PuB. HEALTH LAW § 2781 (Consol. Supp. 1990).

246. See

249. N.Y.
250. Id.
251.

PUB. HEALTH LAW

§ 2781(6)(a) (Consol. Supp. 1990).

IOWA CODE § 141.22(5)(a) (1989).

252. WASH. REV. CODE ANN. § 70.24.105(2)(d) (West Supp. 1991).
253. W. VA. CODE § 16-3C-2(e)(1) (1991).
254. IDAHO CODE § 39-5408 (1991).
255. OR. REV. STAT. § 677.370 (1989).
256. CAL. HEALTH & SAFETY CODE § 1621.5(a) (West 1990); TEX. PENAL CODE ANN.

§

22.012 (Vernon Supp. 1991). In California a donor who knows he has A.I.D.S. or is HIV
positive may be imprisoned for up to six years. CAL. HEALTH & SAFETY CODE § 1621.5(a)
(West 1990).
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testing for HIV, and the Director of Public Health must promulgate
257
guidelines to prevent HIV transmission by artificial insemination.

In Florida, the HIV testing statute is not specific for semen, but
HIV testing of "tissue for transfusion or transplantation" is required. 8 Since semen is a tissue for transfer, it is included by implication. The statute expressly excludes from testing requirements the
semen of the recipient's husband, however.259
Both Montana and Ohio require HIV tests on all prospective
semen donors.260 Georgia, Kentucky, North Carolina and Oklahoma
have similar statutes requiring HIV testing and donor notification if
the test results are positive. 26' Kentucky also requires the practitioner to inform the recipient of the risk of HIV infection during an
AID procedure.2 62 North Carolina relieves a sperm donation facility
of civil or criminal liability for A.I.D.S. transmission if the facility
has complied with statutory requirements for HIV testing and has
informed donors about risks of A.I.D.S. transmission.263
In addition to requiring HIV testing, both Delaware and Illinois
require sperm donation facilities to file with a state registry.264 Maryland requires that HIV tests on donors be performed only in stateapproved laboratories and that the donor must be informed of positive test results. 265
Wisconsin requires sperm donation facilities to test for HIV in
sperm donors.2 66 If the test is negative, the donor must be re-tested
no sooner than 90 days later.2 67 The donor may not donate during
the intervening 90 day period.268 If the second test is negative, he
may donate semen, but he must be re-tested every three months
from the date of the second test.269
Louisiana and Michigan statutes are similar to each other. Both
257. R.I. GEN. LAWS § 23-1-38 (1989).
258. FLA. STAT. ANN. § 381.6105(1) (West Supp. 1991).
259. Id. at § 381.6105(3)(b).
260. MONT. CODE ANN. § 50-16-1008 (1) (1989); OHIO REV. CODE ANN. § 3701.246
(Baldwin Supp. 1990).
261. GA. CODE ANN. § 44-5-151(b), (c) (Harrision 1990); 1990 Ky. REV. STAT. ANN. §
311.281(1), (6) (Baldwin 1991); N.C. GEN. STAT. § 130A-148(d), (g) (1989); OKLA. STAT.
ANN. tit. 63, § 2151.1 (West Supp. 1991).
262. Ky. REV. STAT. ANN. § 311.281(7) (Baldwin 1991).
263. N.C. GEN. STAT. § 130A-148(e) (1989).
264. DEL. CODE ANN. tit. 16, § 2801(a), (b) (Supp. 1990); ILL. ANN. STAT. ch. 127,
para. 55.45, 55.46 (Smith-Hurd 1991).
265. MD. HEALTH-GENERAL CODE ANN. § 18-334(b)(2)(i), (ii), (c)(1) (1990).
266. WIS. STAT. ANN. § 146.025(2)(a)(lr) (West 1989 & Supp. 1990-91).
267. Id.
268. Id.
269. Id.
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states require that semen donations be frozen for six months, during
which time the donors may not donate. 7 If the required HIV test is
negative, the donor may participate in the program, but he must be
retested every six months.27 '
c. Comprehensive Testing Required.-Indiana's donor
screening statutes require a practitioner to test for three STD's
before the donor contributes a semen sample.2 72 Specifically, the donor must be tested for HIV, syphilis and hepatitis-B.2 73 Significantly,
all recipients must be tested for the same diseases at least once a
year. 74 All semen samples must be frozen and quarantined for at
least 180 days and the donor must then be retested for HIV.2 5 If a
recipient indicates that she and the donor are in a "mutually monogamous" relationship, the donor need only be tested annually.2 7 Donors also must provide certain information to the practitioner, including the donor's name, address and birth date.2 77 The practitioner
must ask the donor to provide his Social Security number.2 78
V.

The Case for Federal Involvement

A.

Authority and Scope

The Constitution does not specifically grant the federal government powers relating directly to medical care, human reproduction,
or family matters. 7 Consequently, the constitutional basis for federal regulation of health matters is narrow. Nevertheless "[w]ith respect to health care in general, and to noncoital reproductive techniques in particular, Congress can influence the development of
medical techniques forcefully in areas where it has direct authority
to get involved." 28 0 First, the federal government can promote
nonregulatory efforts, such as recommendations and guidelines, by
government agencies, professional societies and research groups. Second, the federal government has regulatory power over health care
270.
333.20179
271.
272.
273.
274.
275.
276.
277.
278.
279.
280.

LA. REV. STAT. ANN. § 40:1062.1(b)(1) (West Supp. 1991); MICH. COMP. LAWS
(Supp. 1991).
Id.
IND. CODE ANN. § 16-8-7.5-6(a) (Burns Supp. 1990).

Id.
CODE ANN. § 16-8-7.5-6(b) (Burns Supp. 1990).
CODE ANN. § 16-8-7.5-7(a) (Burns Supp. 1990).
CODE ANN. § 16-8-7.5-7(b) (Burns Supp. 1990).
CODE ANN. § 16-8-7.5-13(a) (Burns Supp. 1990).
CODE ANN. § 16-8-7.5-13(b) (Burns Supp. 1990).
See CHOICES, supra note 27, at 176.
See CHoIcEs, supra note 27, at 176-77.
IND.
IND.
IND.
IND.
IND.

§
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under the Taxing & Spending and Commerce Clauses of the
Constitution. 8'
The Constitution gives Congress the power "to lay and collect
Taxes" for the "general Welfare of the United States. 2 82 One indirect way that Congress could promote improved donor screening
practices would be to devise a comprehensive set of recommendations and to condition state receipt of federal government grants
upon the state's enactment of the recommendations into law. 283
1. Sexually transmitted diseases.-Most of the federal government's power to regulate public health derives from the Commerce Clause, which gives the federal government considerable
power to regulate interstate and international health.2 84 The federal
government's authority to control the spread of contagious diseases
rests with the Secretary of the Department of Health and Human
Services.2 85 Thus, in the interest of controlling the spread of STD's,
the federal government could regulate donor screening. However, if
the regulation is challenged, courts will presume that a state's response to a proven health risk is valid unless the federal government
proves that a state's response was medically unsound.2 86
Much discussion has focused on the federal government's power
to control the spread of A.I.D.S. by using broad-based mandatory
testing and screening procedures.287 The issues include potential discrimination conflicts resulting from disclosure of test results, the individual's right to privacy, and the government's interest in protecting the public's health. 88 It is questionable whether mandatory
testing of the entire population for A.I.D.S. would be beneficial because the link between administering HIV tests and reducing the
spread of A.I.D.S. is rather tenuous.2 8 9 Therefore, the government
281.
282.
283.
of federal
284.
285.
286.

U.S. CONST. art. I,

§ 8, cls. 1, 3.

Id. cls. 3.
See CHOICES, supra note 27, at 177. This would be the "carrot on a stick" method
government control.
See CHOICES, supra note 27, at 180; Banks, supra note 247, at 21.
See Banks, supra note 247, at 22.
See Banks, supra note 247, at 23.

287. See generally Banks, supra note 247, at 22.
288. See Banks, supra note 247, at 33-34.

289. See Banks, supra note 247, at 26. Mandatory screening of large segments of the
population for contagious diseases achieves the state's interest in reducing the spread of such
diseases when (a) therapeutic intervention is available or (b) when infectivity puts others at
risk through casual contact. Banks, supra note 247, at 27-28 (citing Ronald Bayer et al., HIV
Antibody Screening. An Ethical Framework for Evaluating Proposed Programs, 256 J.A.M.A.

1768, 1770 (1986)). Currently there is no cure for A.I.D.S. and research indicates that the
virus does not spread by casual contact. Banks, supra note 247, at 34. Therefore, the nexus
between government action and its supposed effect would be poorly defined. The benefit to
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may, in some cases, come close to exceeding its regulatory power.
The Commerce Clause also gives the federal government the
authority to regulate products that travel interstate."9 Many sperm
donation facilities ship their products between states or at least have
the potential to do so.291 Therefore, regulation uinder the Commerce
Clause would be appropriate in these circumstances.
With respect to health matters, the Food and Drug Administration (FDA) regulates drug and medical devices to ensure that they
are safe and effective.292 Under the Food, Drug and Cosmetic Act,
the FDA is authorized to establish standards for biological products. " ' The Act defines a "biological product" as any "virus, therapeutic serum, toxin, antitoxin or analogous product applicable to the
prevention, treatment or cure of a disease or injury of man."2 94 Although the definition does not expressly mention "semen," the
phrase "analogous product" easily could be interpreted to include
semen samples, especially since the recent practice of freezing semen
samples involves washing the fresh semen before cryo-preservation in
glycerol. 9 5 The straws containing the frozen semen derivative could
easily be categorized as a "biological product" which is applicable to
the "treatment or cure" of human infertility diseases.
The Drug and Cosmetic Act requires HIV testing for whole
blood.2" 6 Since the implementation of these requirements in 1985,
the nation's blood supply has been virtually free of HIV-associated
risks and is estimated by the Public Health Service to be "among the
safest in the world." 297 The nexus between federal regulation of
blood products by HIV testing and the government's goal of containing the spread of infectious disease is clear in the case of requiring
testing of blood samples, because HIV-infected blood samples are
discarded, therefore preventing spread of the disease. 98 Further,
testing donated blood, i.e. a "product," is less intrusive on individual
rights than would be a general plan to test all people for HIV.
society would be small and probably outweighed by the discriminatory burden imposed on
individuals identified as HIV carriers. Banks, supra note 247, at 26.
290. U.S. CONST. art. I, § 8, cls. 3.
291. See Debate, supra note 14, at 26.
292. Authority derives from the Department of Health and Human Services' power to
enforce the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 301 et. seq. (1972 & Supp.
1990) and the Fair Packaging and Labelling Act, 16 U.S.C. § 1453 (1972 & Supp. 1990).
293. 21 C.F.R. § 610 (1989).
294. 21 C.F.R. § 600.3(h) (1989).
295.

See supra note 50.

296. 21 C.F.R. § 610.45 (1990); 21 C.F.R. § 640.5(f) (199'3).
297. See U.S. Public Health Service, Report of the Workgroup on Blood and Blood
Products, 103 PUB. HEALTH REP. 58 (1988).

298. See Banks, supra note 247, at 33.
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Donated blood and donated semen are both human tissues.
Once donated they can be construed as "products" subject to regulation by the FDA. In the case of donated semen, however, the picture
is not as clear because donated semen would not be the product that
would be tested for many contagious diseases. To test for HIV, the
donor's blood -

not a product in this case -

would need to be

tested. Still other pathogenic organisms are best detected by testing
urine samples.2 99 Nevertheless, courts probably could conclude that
Congress or the FDA reasonably believed that testing a donor's
blood or urine for disease would eventually prohibit the use of infected semen, which would also prevent the spread of contagious
diseases.3 0
Most significantly, testing semen donors is not analogous with
mandatorily testing large segments of the population. The semen donor makes a conscious choice to contribute semen. If he were informed in advance that his semen, blood or urine would be tested for
the presence of STD's, the testing procedure would not be as invasive because he could refuse to participate.
The federal government has the authority under existing acts
and regulations to require that semen donors' blood, urine or semen
be tested for the presence of STD's. Because most large semen donation facilities already screen for STD's and selected genetic defects,
federal regulation would not be additionally burdensome. On the
other hand, federal regulation would require the small scale facilities
to upgrade their practices. Therefore, the nexus between the regulation and the desired effect would be close.
2. Genetic Diseases.-Creatinga regulatory scheme to detect
genetic diseases is more troublesome. The human genome comprises
at least 30,000 structural genes.301 Most people carry between three
and five lethal recessive genes. 30 2 Therefore, everyone is potentially a
299. See discussion of Neisseria gonorrhoeae and Chlamydia trachomatis,supra notes
137-151 and accompanying text.
300. See Damnie, infra note 302, at 804-05. "In upholding state power to protect public
health at the expense of individual rights, courts have almost universally applied a minimum
scrutiny test for determining the constitutionality of various state actions." Damme, infra note

302, at 804-05 (citing City of New Orleans v. Dukes, 427 U.S. 297, 303 (1976)). The appro-

priateness of the rational basis test is underscored in light of the donor's voluntary decision
whether to contribute semen.
301. See A & K, supra note 55, at 755. The "genome" is the total complement of genes
for a species. STEDMAN'S 23RD, supra note 33, at 577. Structural genes are those that produce
an enzyme product. Other types of genes, termed regulator genes, produce no product but act
like switches to activate or inactivate the structural genes.
302. Catherine J. Damme, Controlling Genetic Disease Through Law, 15 U.C. DAVIS
L.R. 801, 808 (1982) [hereinafter Damme] (citing Morton, Crow & Muller, An Estimate of
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carrier for genes that cause severe genetic disease.303 Because more
than 2,000 genetic diseases have been identified, in theory all semen
donors should be tested for all diseases. Such comprehensive testing
would be impractical, of course. Even if testing for a select group of
defects were effected, issues to be resolved would still exist, such as
which diseases donors should be tested for, in which groups and at
what cost. Unlike infectious diseases, which in theory can affect everyone equally, genetic diseases are hereditary and often have a
strong ethnic or racial component.304 Therefore, opportunities to discriminate on the basis of race or ethnicity would be increased." 5
It would be inappropriate for the federal government to regulate
testing for genetic diseases. A better approach would be for the CDC
to issue recommendations suggesting the need to take a comprehensive genetic history of the donor and his family. The person taking
the history should be trained in genetic counseling and should orally
administer the questions to the potential donor.
B. Current Efforts
The FDA is currently examining the question of whether to regulate donor screening practices.30 6 The Agency fully recognizes the
number and complexity of the issues involved in semen donor regulation, and has actively sought commentary and guidance from practitioners and researchers in the AID profession. 307
VI. Specific Recommendations for Federal Regulation
The following definitions and screening procedures should be included in a proposal for federal regulation of donor screening practices. These recommendations are an integration of the guidelines
suggested by the A.F.S., the French C.E.C.O.S., and prominent
researchers.3 o8
1. Definitions.
Mutational Damage in Man from Data on Consanguinous Marriages, 42 PROC. NAT'L ACAD.
Sci. 855 (1956)). Lethal recessive genes are genes that are not expressed when only one copy
of the deleterious recessive gene is present (e.g., Aa genotype, cystic fibrosis). When two copies
of the gene are present (e.g., aa), the individual dies from the condition.
303. Id.
304. Id. at 807.
305. Id.
306. Telephone interview with Ann Wion, Associate Chief -Counsel for Drugs & Biologics, Food and Drug Administration, Rockville, MD (Oct. 25, 1990).
307. Id. Ms. Wion thought that the FDA might provide guidance on this question during 1991.
308. See generally 1990 Guidelines, supra note 26; Barratt, supra note 1; Greenblatt,
supra note 7; Hummel, supra note 4.

SCREENING PRACTICES

a. Semen donation facility: any sperm bank, health
care facility, medical school, clinic or physician's office
that collects, processes, packages or ships semen.
2. Scope. Proposed regulations should
a. govern screening for sexually transmitted diseases;
b. include authority to test a donor's blood, semen and
urine for the presence of STD's, as provided below.
3. Frequency of Testing. Tests for STD's should be conducted at the time of initial donation. Donors should be
retested every six months for all STD's. Each time a donor
donates a sample, he should be asked if he or his intimate
partner has changed sexual partners since the last donation. If the answer is "Yes," he should be retested or excluded from the program.
4. Specific Diseases to be Screened. HIV, hepatitis-B,
cytomegalovirus, genital herpes, human papilloma virus,
gonorrhea, syphilis, Chlamydia, Group B Streptococcus,
the genital mycoplasma diseases, and Trichomonas.
5. Record Keeping.
a. Donors should be notified if they test positive to
one or more tests; donors should be advised of treatment
options and prognoses.
b. Confidential, coded, anonymous records should be
kept permanently for each donor, indicating results of
tests. Anonymous records should be accessible to all recipients and to any children conceived with a donor's semen.
c. Donors should be limited to ten pregnancies.
VII. Conclusion
The primary objective for practitioners of AID and for governments that seek to regulate donor screening should be to preserve the
woman's health and ensure the health of her child. Many sexually
transmitted diseases cause morbidity to the female reproductive
tract, as well as to fetuses, newborns and older children. Therefore,
it is in the interests of women and children to prevent their infection
with sexually transmitted diseases. To reach this goal, professional
AID practitioners have formulated their own standards and
guidelines.
The efforts of the profession to meet this goal have been inconsistent. Because state regulations are variable or non-existent, the
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federal government should prescribe and regulate semen donor
screening for sexually transmitted diseases. Federal regulations probably would result in a significant reduction in t:he spread of contagious diseases between donors, recipients and children involved in
AID procedures. Through regulation, the twin goals of preserving
the woman's health and ensuring the health of her child will be met.
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SCREENING PRACTICES

Appendix A. Sexually Transmitted Pathogens in Semen and
Reported Transmission by Semen Donorsa

Pathogen
VIRUSES
HIV
Hepatitis B
Cytomegalovirus
Herpes simplex
Human Papilloma
MYCOPLASMAS
Mycoplasma
hominis
Ureaplasma
urealyticum
BACTERIA
Chlamydia
trachomatis
Neisseria
gonorrhoeae
B-Streptococcus
Treponema
pallidum
PROTOZOAN
Trichomonas
vaginalis

Presence
in Semen

Reported
Transmission
by Donor
Semen

Likelihood of
Transmission
If Not Yet
Reported

Yes
Yes
Yes
Yes
Uncertain

Yes
Yes
Not reported
Yes
Not reported

High

Yes

Yes

Yes

Yes

Yes

Yes

Yes
Yes

Yes
Yes

Probable

Not reported

'Modified and updated from Greenblatt, supra note 7, at 358.

Low

Uncertain

